Polymyxin B nonapeptide, prepared by enzymic removal of the fatty acyl diaminobutyric acid side chain from polymyxin B, was about 100-fold less toxic to K562 cells than polymyxin B. MICs of polymyxin B nonapeptide against a test panel of bacteria were 2-to 64-fold lower than those of polymyxin B.
Polymyxin B is a peptide antibiotic containing a heptapeptide ring and a fatty acylated tripeptide side chain. It is a broad-spectrum antibiotic with greater activity against gramnegative than gram-positive bacteria (4) . The antibacterial activity of polymyxin B results from its ability to bind and disorganize the outer membrane of gram-negative bacteria, resulting in changes to the membrane permeability barrier (4) . Immobilized polymyxin B can disrupt the Escherichia coli outer membrane permeability barrier, indicating that penetration of the outer membrane is not required for activity (3) . The inhibition of polymyxin B binding to outer membranes by divalent cations and the polycationic nature of polymyxin B suggest that antibiotic-outer membrane interactions are electrostatic (4) .
Polymyxin B nonapeptide (PMBN), a derivative of polymyxin B which lacks the side chain terminal fatty acyl diaminobutyrate, binds with relatively high affinity to the outer membrane (6) , disrupts the outer membrane (5) , and sensitizes gram-negative bacteria to several hydrophobic antibiotics (8) and serum complement (7) .
Alterations in the fatty acyl side chain of the related antibiotic, colistin, influence both antimicrobial activity and acute toxicity toward mice (1) . In the present study, the eucaryotic cytotoxicity against K562 
